Both parties expect the transaction to be completed early in the second calendar quarter of this year, Mallinckrodt’s third fiscal quarter.
The transaction is expected to add at least $150 million in net sales and be accretive to Mallinckrodt’s fiscal year 2015 adjusted diluted earnings per share by at least 25 cents per share, according to a news release.
“We continue to move decisively in line with our strategic roadmap —building on key growth platforms and using our unique ability to manage complexity to unlock untapped additional value from diverse products and environments,” Mark Trudeau, president and CEO of Mallinckrodt, said in the release. “With this expansion into respiratory neonatal critical care we expect to further broaden our touch points in the hospital market, and at the same time diversify our portfolio with durable assets that play vital roles in the treatment of vulnerable patient populations.”
More articles on hospital transactions and valuation issues:
Riverview Hospital Association finalizes merger with Aspirus
University Hospitals eyes adding Samaritan Regional Health System
CHS to divest 2 South Carolina hospitals
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
